Chewy, Inc. research snapshot
CHWY AI stock analysis as of the August 3, 2026 data cutoff reads Chewy as a scaled online pet commerce platform with a durable Autoship habit, 21.5 million active customers, record quarterly profitability, and strong free cash flow, trading at a moderate forward valuation. The stock closed at $22.60 on July 31, 2026, with a market capitalization near $9.25 billion, re-verified during this full refresh as $22.60 times 409.42 million shares outstanding, matching the StockAnalysis.com quote and statistics pages. Q1 fiscal 2026, reported June 10, 2026, delivered net sales of $3.357 billion up 7.7%, gross margin of 30.1% up 50 basis points, adjusted EBITDA of $253.1 million at a record 7.5% margin up 130 basis points, and free cash flow of $70.8 million up 45%. Management moderated full-year fiscal 2026 net sales guidance to $13.40 billion to $13.55 billion with a 6.6% to 6.8% adjusted EBITDA margin, added Q2 net sales guidance of $3.30 billion to $3.33 billion, and launched a $600 million Term Loan B with a net leverage target below 2x adjusted EBITDA. Technically the stock now sits above its 20-day average near $21.41 and its 50-day average near $20.52 after the June recovery, but below the 100-day near $22.81 and the 200-day near $27.27. This CHWY AI stock analysis uses scenario ranges and dated source checks for information only, not a guaranteed stock price prediction or investment advice.
Current price
$22.60 at the July 31, 2026 close
Market cap
$9.25 billion verified market cap
AI score
66 / 100
Rating
Recurring pet commerce with record profitability and improving cash flow, but consumer and growth headwinds remain
Trend status
Above the 20-day and 50-day moving averages after the June recovery, still below the 100-day and 200-day averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Chewy combines a large online pet assortment, pharmacy and health offerings, customer service, fulfillment, private brands, and Autoship replenishment for recurring pet needs. Q1 FY2026 gross margin reached 30.1% and adjusted EBITDA margin reached a record 7.5%. | High |
| Moat | The practical moat is built from customer habit, Autoship data, fulfillment scale, selection, trust in prescriptions, and cross-selling across pet commerce and care. It is useful but not impregnable against Amazon, Walmart, Petco, PetSmart, manufacturers, and local veterinary networks. | Medium-high |
| Management | Sumit Singh has led the shift toward profitable growth, buybacks, health, and vet care. CFO Chris Deppe has driven the SmartPak and Modern Animal acquisitions and the $600 million Term Loan B, while the BC Partners dual-class structure keeps majority voting control concentrated. | Medium |
| Financial trend | Fiscal 2025 net sales reached $12.60 billion with adjusted EBITDA of $719.2 million and free cash flow of $562.4 million. Q1 FY2026 net sales grew 7.7%, adjusted EBITDA margin hit 7.5%, and free cash flow rose 45% to $70.8 million. | High |
| Valuation | At $22.60, CHWY traded near 37.75x trailing GAAP EPS but only 14.12x forward earnings, 0.72x sales, 15.83x free cash flow, and 0.49x PEG in the August 2, 2026 StockAnalysis snapshot, which is moderate for the margin trajectory. | Medium-high |
| Technical trend | The stock closed above its 20-day average near $21.41 and 50-day near $20.52, with 14-day RSI near 59.08 and ADX near 24.32, but remains below the 100-day near $22.81 and the 200-day near $27.27. | Medium |
| Risk level | Key risks include softer discretionary pet spending, premiumization and attach-rate pressure, customer acquisition cost, freight and fuel surcharges, thin GAAP margins, competition, new leverage from the Term Loan B, Modern Animal integration, and short interest near 50% of float. | Medium-high |
| AI confidence | Descriptive confidence is high because the main financial and operating facts are supported by SEC or company filings and a separate market-data source. Forward scenario confidence is medium. | High data confidence |
| Investment certainty | The business has recurring demand, record margins, and rising cash flow, but the equity needs continued customer growth and margin delivery to justify the price. This is a conditional research setup, not a buy signal. | Medium |
CHWY AI stock forecast
The CHWY AI stock forecast uses the July 31, 2026 close of $22.60 and consensus adjusted EPS of about $1.53 for fiscal 2026 as the anchor. A three-year scenario model with adjusted EPS growth of roughly 20%, 10%, and 3% and exit multiples of 20x, 15x, and 11x points to a bullish area near $50, a base area near $31, and a bearish area near $18. The ranges below are deliberately wide and exclude dividends because Chewy currently pays none.
$42 to $52
More likely if active customer adds stay near the middle of the 150,000 to 250,000 quarterly range, Autoship remains above 84% of sales, premiumization recovers, gross margin keeps expanding, Chewy Health and Chewy Vet Care lift customer lifetime value, and the market supports a premium forward multiple near 20x.
$27 to $34
More likely if net sales land near the fiscal 2026 guidance range, adjusted EBITDA margin holds near 6.6% to 6.8%, active customers and Autoship grow at a slower but positive rate, and investors hold the stock near a 14x to 16x forward multiple, consistent with the analyst average target near $31.
$15 to $20
More likely if consumer pressure deepens, NSPAC and premiumization keep falling, customer acquisition becomes more expensive, Modern Animal consumes cash without improving retention, the new Term Loan B raises interest costs, or the market compresses the multiple toward 11x forward earnings.
CHWY AI technical analysis
CHWY AI technical analysis is mixed-to-improving as of the August 3, 2026 cutoff. The July 31 close at $22.60 sits above the 20-day moving average near $21.41 and the 50-day near $20.52 after a recovery off the June lows, but below the 100-day near $22.81 and well below the 200-day near $27.27. RSI near 59 and ADX near 24 show a developing trend rather than a strong breakout, while the 52-week range of $17.40 to $43.50 and a beta of 1.44 keep risk elevated.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $22.60 | StockAnalysis.com recorded the July 31, 2026 close. All technical levels are snapshots, not permanent support or resistance. |
| Near support | $21.40 to $21.50 | The 20-day moving average sits near $21.41, and July 20 to July 23 trading held this area before the late-July advance. |
| Next support | $20.50 to $20.90 | The 50-day moving average is near $20.52, and July 14 to July 24 sessions consolidated around $20.35 to $20.93. |
| Deeper support | $19.60 to $20.00 | July 1 and July 13 lows held near $19.95 to $20.04, with the June 30 close at $19.65 forming the base of the recovery. |
| Major support | $17.40 | The 52-week low set in June 2026. A sustained break below it would reset the recovery thesis. |
| Near resistance | $22.80 to $23.30 | The 100-day moving average is near $22.81, and the July 29 high of $23.62 with a close of $23.30 caps the recent rally. |
| Higher resistance | $24.50 to $25.50 | May 2026 trading clustered in this area before the decline, making it a reference zone if the stock clears the 100-day average. |
| Moving averages | 5-day $22.69, 20-day $21.41, 50-day $20.52, 100-day $22.81, 200-day $27.27 | Barchart technical snapshot and StockAnalysis statistics reviewed July 31, 2026. |
| Momentum | RSI 59.08, ADX 24.32 | 14-day RSI is neutral-to-firm and 14-day ADX near 24 confirms a developing trend rather than a range, but not yet a strong breakout. |
| Volume | 20-day average about 7.7 to 7.9 million shares | StockAnalysis lists about 7.73 million and Barchart about 7.89 million for the 20-day average. The July 31 session traded about 4.86 million shares, below average. |
| Volatility | ATR $1.03; historic volatility near 48%; beta 1.44 | 14-day ATR is about 4.5% of price and 14-day historic volatility near 48.2%, so position sizing should account for large swings around earnings on September 9, 2026. |
| Invalidation | Sustained close below $20.00 | A break below the 20-day and 50-day averages toward $19.60 to $20.00 would weaken the recovery, and a close below $17.40 would invalidate it. |
CHWY AI trading strategy
The CHWY AI trading strategy below is a rules-based research framework, not personalized advice. It combines price confirmation with customer, margin, cash-flow, and healthcare integration checks, and it should be paired with fresh chart data and a defined invalidation level.
Watch for CHWY to reclaim and hold the 100-day average near $22.81 with volume above the 20-day average. A later move toward $24.50 to $25.50 would need improving revenue guidance and continued margin delivery.
A failed breakout followed by a close below $21.40 should reduce confidence. A close below $20.00 weakens the setup, and a break below $17.40 invalidates the recovery framework.
If CHWY pulls back toward $20.50 to $21.50 while active customers, Autoship, gross margin, and free cash flow remain healthy, compare the price with updated earnings power before treating the level as support.
Do not average down solely because the stock is far below its 52-week high. A weakening customer trend, lower fiscal 2026 guidance, or rising interest costs can make historical support unreliable.
Track Q2 fiscal 2026 results due September 9, 2026 against the $3.30 billion to $3.33 billion sales guide, the 6.3% to 6.4% adjusted EBITDA margin, and adjusted EPS near $0.36, plus full-year sales of $13.40 billion to $13.55 billion, active customer adds, Autoship sales, gross margin, free cash flow, Term Loan B interest, buybacks, and Modern Animal integration.
Reduce confidence if growth depends on share-based compensation adjustments or cost cuts instead of customer retention, healthy gross profit, cash conversion, and durable operating leverage.
Investment research summary
Customers pay Chewy for convenient replenishment of food, supplies, prescriptions, and pet-health products. The core value is a trusted digital relationship that reduces the effort of managing recurring pet needs. Autoship turns part of that relationship into repeat demand, but the company still operates a physical inventory and fulfillment network.
The moat is practical rather than absolute. Chewy has 21.5 million active customers, about 190,000 product and service offerings, relationships with roughly 4,000 brands, Autoship behavior, pharmacy trust, fulfillment scale, and a strong service reputation. Amazon, Walmart, Petco, PetSmart, manufacturers, and local clinics can still compete for the same customer.
The thesis fails if customer acquisition costs rise faster than lifetime value, pet spending becomes more discretionary, premiumization and attach rates keep falling, freight and fuel surcharges pressure the roughly 30% gross margin, or Autoship growth hides weaker new-customer economics. Modern Animal and the new leverage can also consume management attention, capital, and cash before their benefits are proven.
Sumit Singh has overseen the move toward profitable growth, higher gross margin, health services, and shareholder returns. Chewy returned about $200 million through share repurchases in Q1 FY2026, closed the SmartPak acquisition, closed Modern Animal to reach 47 clinics, and launched a $600 million Term Loan B with a net leverage target below 2x adjusted EBITDA. The 2026 proxy still shows a dual-class structure in which BC Partners holds majority voting control, so governance alignment deserves monitoring.
Pet ownership, recurring consumables, prescription fulfillment, and digital convenience support a durable category. Chewy is extending into veterinary care, with pet healthcare TAM estimated near $54 billion including over $40 billion in in-clinic products and veterinary services, and roughly 60 clinics expected exiting fiscal 2026. The opportunity is large, but care delivery has different staffing, regulatory, and operating requirements from e-commerce.
At $22.60, CHWY looked expensive on trailing GAAP earnings at about 37.75x but moderate on forward earnings at about 14.12x, sales at about 0.72x, and free cash flow at about 15.83x. The margin of safety depends on turning record adjusted EBITDA and free cash flow into durable GAAP earnings without excessive dilution, acquisition spending, or interest costs.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CHWY closing price | $22.60 | StockAnalysis.com real-time quote | July 31, 2026 close |
| Market capitalization and shares | $9.25 billion; 409.42 million shares | StockAnalysis.com statistics | August 2, 2026 |
| Fiscal 2025 net sales | $12.60 billion, up 6.2% year over year or 8.3% on a normalized 52-week basis | Chewy Q4 and full year fiscal 2025 results | March 25, 2026 |
| Fiscal 2025 adjusted EBITDA and free cash flow | $719.2 million adjusted EBITDA; $562.4 million free cash flow | Chewy Q4 and full year fiscal 2025 results | March 25, 2026 |
| Fiscal 2025 customers and Autoship | 21.327 million active customers; Autoship $10,497.1 million or 83.3% of net sales | Chewy Q4 and full year fiscal 2025 results | March 25, 2026 |
| Q1 FY2026 net sales and gross margin | $3.357 billion; 30.1% gross margin | Chewy Q1 FY2026 results | June 10, 2026 |
| Q1 FY2026 adjusted profitability | Adjusted EBITDA $253.1 million at 7.5% margin; adjusted diluted EPS $0.43 | Chewy Q1 FY2026 results | June 10, 2026 |
| Q1 FY2026 cash flow | Operating cash flow $108.5 million; free cash flow $70.8 million, up 45.4% | Chewy Q1 FY2026 results | June 10, 2026 |
| Q1 FY2026 active customers and Autoship sales | 21.497 million active customers, up 3.6%; Autoship sales $2,832.6 million, up 10.5%, at 84.4% of net sales | Chewy Q1 FY2026 results | June 10, 2026 |
| Q1 FY2026 balance sheet | $485.2 million cash plus $34.9 million marketable securities for $520.1 million combined, with over $1 billion total liquidity | Chewy Q1 FY2026 results | May 3, 2026 balance-sheet date |
| Fiscal 2026 guidance | Net sales $13.40 billion to $13.55 billion; adjusted EBITDA margin 6.6% to 6.8% | Chewy Q1 FY2026 earnings call | June 10, 2026 |
| Q2 FY2026 guidance | Net sales $3.30 billion to $3.33 billion; adjusted EBITDA margin 6.3% to 6.4%; adjusted EPS about $0.36 | Chewy Q1 FY2026 earnings call | June 10, 2026 |
| Term Loan B and leverage target | $600 million Term Loan B launched June 10, 2026; net leverage target below 2x adjusted EBITDA | Chewy Q1 FY2026 earnings call | June 10, 2026 |
| Modern Animal and Chewy Vet Care | Modern Animal closed after quarter end, bringing the clinic footprint to 47; about 60 clinics expected exiting fiscal 2026 | Chewy Q1 FY2026 earnings call | June 10, 2026 |
| Analyst consensus and price target | Buy consensus across 25 analysts with an average target of $31.05, low $22 and high $42 | StockAnalysis.com forecast, S&P Global and TipRanks data | July 30, 2026 |
| Analyst rating mix, July 2026 | 12 Strong Buy, 8 Buy, 5 Hold, 0 Sell out of 25 analysts | StockAnalysis.com recommendation trends | July 2026 |
| Technical snapshot | 50-day $20.52; 200-day $27.27; RSI 59.08; beta 1.44; 20-day average volume about 7.73 million | StockAnalysis.com statistics and Barchart technical analysis | July 31, 2026 |
| Short interest | 27.33 million shares short, 6.68% of shares outstanding, 50.23% of float, 2.64 days to cover | StockAnalysis.com short selling statistics | August 2, 2026 |
| Voting control | BC Partners held majority voting power through the dual-class structure in the 2026 proxy table | Chewy 2026 proxy statement | May 13, 2026 ownership date |
This page is an information tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenarios based on available data and assumptions that may be wrong. Market prices, technical levels, financial results, and company guidance can change after the August 3, 2026 data cutoff. Verify current filings and market data before making any decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
